The clinical activity of mirvetuximab has been evaluated across several trials in patients with platinum-resistant epithelial ovarian cancer, where FRα expression represented a crucial biomarker for therapeutic efficacy [7,8,9,10,11,12,13]. The gene discussed is FOLR1; the disease is ovarian carcinoma.